Q2 net loss $445M; revs up 9% to $1.04B; Jakafi guidance raised; $2B buyback completed

INCYTE CORP

2024-Q2 EPS reported -$1.24 revenue$1,924,648,000

Total revenues $1,044M (+9% YoY); Jakafi $706M (+3%), Opzelura $122M (+52%).
GAAP net loss $444.6M vs $203.5M income in Q2 2023; non-GAAP net loss $396.1M.
Completed $2.0B share repurchase (33.3M shares at $60 each) in June 2024.
Raised low end of 2024 Jakafi revenue guidance to $2,710-$2,750M; revised R&D guidance up.
Discontinued development of oral PD-L1, LAG-3, TIM-3, LAG-3xPD-1; focus on high-impact programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.